NightHawk Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.723126 million compared to USD 0.058861 million a year ago. Net loss was USD 13.13 million compared to USD 13.26 million a year ago. Basic loss per share from continuing operations was USD 0.38 compared to USD 0.41 a year ago. Diluted loss per share from continuing operations was USD 0.38 compared to USD 0.41 a year ago. Basic loss per share was USD 0.5 compared to USD 0.52 a year ago. Diluted loss per share was USD 0.5 compared to USD 0.52 a year ago.
For the nine months, sales was USD 2.15 million compared to USD 0.290259 million a year ago. Net loss was USD 39.81 million compared to USD 28.21 million a year ago. Basic loss per share from continuing operations was USD 1.3 compared to USD 0.95 a year ago. Diluted loss per share from continuing operations was USD 1.3 compared to USD 0.95 a year ago. Basic loss per share was USD 1.53 compared to USD 1.1 a year ago. Diluted loss per share was USD 1.53 compared to USD 1.1 a year ago.